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InﬂammationAbstract Chronic obstructive pulmonary disease (COPD) is a chronic inﬂammatory disease of the
lung. Some of the inﬂammatory markers such as C-reactive protein (CRP), leukocyte count are
associated with COPD. The aim of this study is to evaluate the role of neutrophil-to-lymphocyte
ratio (NLR) as new inﬂammatory marker in COPD patients in comparison with the other well-
known inﬂammatory markers. We prospectively evaluated neutrophil-to-lymphocyte ratio, CRP
and ESR in 60 patients with stable COPD and 68 COPD patients during acute exacerbation and
60 sex- and age-matched healthy controls. We found that NLR values during acute exacerbation
of the disease were signiﬁcantly higher than those during stable period (P< 0.001). NRL values
of the stable COPD patients were signiﬁcantly higher than those of the controls (P< 0.001).
NLR values were also positively correlated with serum CRP levels, ESR, and WBC.
Conclusion: NLR can be used as a new inﬂammatory marker for assessment of inﬂammation in
COPD patients. It is a good predictor for exacerbation of COPD. It is a quick, cheap, easily mea-
surable marker with no need for a special request.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
One of the characteristic features of COPD is acute exacerba-
tions, which usually are associated with increased inﬂamma-
tion due to infections (bacterial, viral and combined viral/
bacteria) and or environmental factors. There is a positive rela-tionship between exacerbations of COPD and hospitalization,
decline in quality of life and mortality rate. Early detection of
acute exacerbation of COPD is essential to avoid these major
complications [1].
Inﬂammation in COPD may be contributed to many cell-
types such as the macrophages, the neutrophils and the lym-
phocytes [2–4].
Neutrophils play an important role in inﬂammatory condi-
tions more than macrophages. Neutrophils are an important
source of proteases, especially reactive oxygen species andtive pul-
2 A.M. Yousef, W. Alkhiaryneutrophil elastase. They are the hallmark of acute inﬂamma-
tion [5] .
Unlike other inﬂammatory biomarkers e.g., ESR and CRP,
the Neutrophil–lymphocyte ratio (NLR) is derived from rou-
tine complete blood count (CBC) tests. It does not need a spe-
cial request. It is also a rapid, easy method, and cost-effective.
Many studies have reported an increase of NLR during the
inﬂammatory conditions in different diseases such as pancre-
atitis, inﬂammatory bowel diseases, and acute coronary syn-
drome [6–10].
To our knowledge few number of studies have been pub-
lished about the relationship between neutrophil lymphocyte
ratio and respiratory diseases.
Our hypothesis is that NLR could be a useful important
inﬂammatory marker that detects the inﬂammatory status dur-
ing acute exacerbations of COPD (AE-COPD) and could iden-
tify early acute exacerbations for early management.
The aim of this study is to evaluate the potential for NLR
to be used as a biomarker of COPD exacerbation.
Study patients
Between February 2014 and November 2015, patients admit-
ted to our department with acute exacerbated COPD were
prospectively enrolled into this study.
The study included 68 COPD patients with exacerbation
(mean age was 49.5 years), 60 patients during stable COPD
(mean age was 48.9 years) and 60 control subjects(mean age
was 48.3 years). The subjects in all groups were males.
Complete blood count (CBC), Erythrocyte sedimentation
rate (ESR), and C Reactive protein (CRP) were measured
from blood samples taken from patients with AE-COPD
(68 patients) within 2 h of admission to the hospital. Three
months later on after an acute exacerbation, CBC, ESR,
and CRP were measured again from the same patients dur-
ing the stable period of COPD (60 patients). Eight patients
were lost during the follow up. The same investigations were
done for the control group. The control group included 60
ex-smokers normal persons. They were matched to patients
regarding age and sex. NLR, CRP and ESR values were
compared among the three groups of the study. NLR was
calculated from the CBC.
Pulmonary function tests were done and both groups of
COPD were staged according to the severity criteria of GOLD
[7]; stage I [FEV1P 80%,], stage II [50% 6 FEV1 < 80%],
stage III [30% 6 FEV1 < 50%] and stage IV [FEV1 < 30%].
Inclusion criteria
Patients with acute exacerbation of COPD, stable COPD
patients with no history of acute exacerbation during the past
3 months.
Exclusion criteria
Exclusion criteria for subject enrollment included: (1) severe
structural lung disease such as tuberculosis; bronchiectasis
(2) a concurrent active inﬂammatory disease other than
COPD; (3) bronchial asthma; (4) having any infectious,
inﬂammatory diseases or malignancy.Please cite this article in press as: A.M. Yousef, W. Alkhiary, Role of neutrophil to
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Chronic Obstructive Lung Disease guidelines if the ratio of
post-bronchodilator forced expiratory volume in 1 s to forced
vital capacity (FEV1/FVC) was <0.7. An exacerbation of
COPD was deﬁned if there was acute deterioration of the
patient’s respiratory symptoms beyond normal day-today vari-
ations, and there was a need for additional steroids or
antibiotics.
Stable COPD was deﬁned as the absence of signiﬁcant
changes in symptom along with no further requirements to
additional treatment or doses of daily inhaler treatment for
3 months.
Statistical analysis
Statistical analyses were performed using SPSS version 15 01.
Independent-samples t-test, paired t-test and Mann–Whitney
U tests were used for the comparison of continuous variables.
Pearson’s correlation was used between NLR and other
inﬂammatory markers. Receiver operating characteristic
(ROC) curves were constructed for the WBC, NLR, CRP,
and ESR variables, and the areas under the ROC curve values
with 95% CIs were calculated and compared with each other.
Optimal cut-off values were determined; sensitivity, and speci-
ﬁcity were calculated with (95% CI). P value 6 0.05 was con-
sidered statistically signiﬁcant.
Results
The characteristics and laboratory ﬁndings of involved sub-
jects in the three groups are outlined in Table 1. There was
no statistical difference among the groups with respect to age
and sex.
NLR, ESR, and CRP were signiﬁcantly higher in the exac-
erbated COPD group compared to stable COPD group and
control group. The mean NLR values of exacerbated COPD
patients, stable and controls were 4.44, 2.36, and 1.45, respec-
tively (P= 0.000) (Table 2). Mean NLR of exacerbated
COPD group was signiﬁcantly higher than those of stable
group and control group (respectively P= 0.000 and
P= 0.000). Pearson correlation analysis indicated a signiﬁcant
correlation of NLR with WBC (r 0.694, P< 0.000), CRP (r
0.609, P< 0.000), and ESR (r 0.714, P< 0.000) (Figs. 1
and 2)
The cutoff for NLR was 3.12. it has 86.7% sensitivity for
detection of COPD exacerbation and 76.7% speciﬁcity
(AUC 0.878, P< 0.001).
The cutoff for CRP was 3.15. It has 80% sensitivity for
detection of COPD exacerbation. and 87% speciﬁcity (AUC
0.825, P< 0.001) (Fig. 3).
The cutoff for ESR was 17.5. it has 60% sensitivity for
detection of COPD exacerbation of COPD and 80% speciﬁcity
(AUC 0.677, P < 0.001).
The cutoff for WBC was 9.5. It has 76.1% sensitivity for
detection of COPD exacerbation and 83.3% speciﬁcity
(AUC 0.781, P< 0.001) (Table 3).
CRP levels were lower than the optimal cut-off value
(CRP < 3.15) in twelve patients who were present during
AE-COPD, six of them (50%) had higher NLR values than
the optimal cutoff NLR (NLR> 3.12). ESR levels were lowerlymphocyte ratio in prediction of acute exacerbation of chronic obstructive pul-
dt.2016.09.006
Table 1 Demographic and laboratory data.
Exacerbation Stable Control P
Number 68 60 60
Age 49.5 (7.49) 48.9 (8.92) 48.3 (8.46) .087
Sex: male % 68 (100) 60 (100) 60 (100)
BMI 32 (2.3) 32 (2.5) 31 (3.5) 0.54
Pulmonary function
FEv1 42.6 (26) 54.3 (27) 83 (12) 0.813
FEv1/fvc% 54 (13) 60 (12) 79 (8) 0.658
Laboratory findings
Leucocytes 11.4 (2.5) 8.2 (2.1) 4.9 (1.3) <0.001
lymphocyte 1.49 2.1 (1.2) 2.4 (.9) <0.001
NLR 4.44 2.36 1.45 <0.001
Hemoglobin g/dl 13.1 (1.9) 15 (3.1) 13.3 (1.8) <0.001
ESR 11.18 3.88 2.13 <0.001
CRP 8.9 1.2 0.22 <0.001
Table 2 Analysis of inﬂammatory markers in the three
groups.
Mean (SD) P
Neutrophil
Control 336.07 (53.88) 0.000
Stable 478.0 (77.69)
Exacerbation 737.330 (160.94)
Lymphocytes
Control 285.33 (186.23) 0.35
Stable 210.0 (43.07)
Exacerbation 178.33 (45.23)
Neutrophil/lymphocyte ratio
Control 1.45 (0.21) 0.000
Stable 2.36 (0.55)
Exacerbation 4.44 (1.61)
WBC
Control 5.14 (0.93) 0.000
Stable 7.37 (1.07)
Exacerbation 10.91 (2.13)
CRP
Control 0.22 (0.11) 0.000
Stable 1.20 (0.51)
Exacerbation 8.9 (2.28)
ESR
Control 3.91(2.13) 0.000
Stable 9.65(3.88)
Exacerbation 19.56(11.18)
ESR erythrocyte sedimentation rate, CRP C-reactive protein, WCC
white blood cell count.
Role of neutrophil to lymphocyte ratio in prediction of acute exacerbation of chronic obstructive pulmonary disease 3than the optimal cut-off value (ESR < 17.5) in twenty-four
patients who were present during AE-COPD, 16 of them
(66%) had higher NLR values (NLR> 3.14). WBC levels
were lower than the optimal cut-off value (WBC< 7880) in
fourteen patients who were present during AE-COPD, six of
them (42.9%) had higher NLR values (NLR> 3.12).Please cite this article in press as: A.M. Yousef, W. Alkhiary, Role of neutrophil to l
monary disease, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcNLR levels were inversely associated with the severity of
airﬂow limitation, as measured by FEV1% predicted and
absolute values (Pearson r= 0.148, P< 0.001 and Pearson
r = 0.176, P < 0.001, respectively).
Discussion
It is well known that the leukocyte count and its subtypes are
inﬂammatory markers [5,6]. On exposure to a physiological
stress the leukocyte count changes in the circulation. The num-
ber of neutrophils increase, while, the number of lymphocytes
decrease. Some authors used the ratio of these subgroups to
each other as a marker of inﬂammation [8,9].
AE-COPD is accompanied with deterioration in lung func-
tion. Acute exacerbation of COPD increases the hospitaliza-
tion rate, decreases the lung function, and deteriorates the
patient’s quality of life. Severe attacks of exacerbated COPD
lead to increased mortality raterker. Presence of a marker
for early detection of the of AE is essential to avoid these
major complications [10]. NLR is a cheap inﬂammatory mar-
ker that can be obtained from the routine laboratory investiga-
tions. It has a predictive and prognostic values in systemic
inﬂammatory diseases such as inﬂammatory bowel disease,
kidney disease, cardiovascular disease, and familial Mediter-
ranean fever [11,12]. We aimed in this study to evaluate the
potential for NLR to be used as a biomarker of COPD
exacerbation.
In the current study, we found that the blood leukocytic
count, ESR and CRP was higher in stable COPD patients than
in healthy subjects. These results indicate that there is a low
grade persistent systemic inﬂammation even in stable COPD
patients. This was described in previous studies [13,14]. In this
study, ESR, serum CRP as markers for inﬂammation showed
a signiﬁcant difference in patients with stable COPD in com-
parison to those with AE. This coincide with other studies that
reported increased levels of CRP and ESR in patients with AE-
COPD as compared with stable COPD patients and controls
[15–16]. However, ESR and CRP measurements are not rou-
tinely viable in clinical practice, especially in emergency serviceymphocyte ratio in prediction of acute exacerbation of chronic obstructive pul-
dt.2016.09.006
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Figure 1 Correlation between C-reactive protein and neutrophil-to-lymphocyte ratio in patients with exacerbated COPD.
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Figure 2 Correlation between ESR and neutrophil-to-lymphocyte ratio in patients with exacerbated COPD.
4 A.M. Yousef, W. Alkhiarydepartments because of the additional time and staff that is
required.
The current study showed that ESR has a low sensitivity
and speciﬁcity in comparison with other tests (Table 2). ThisPlease cite this article in press as: A.M. Yousef, W. Alkhiary, Role of neutrophil to
monary disease, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcindicates that ESR has little value in the diagnosis of AE. This
ﬁnding was coincide with the results of Odak and McNicholas
[17] who had reported that the sensitivity and speciﬁcity of
ESR alone for diagnosis of inﬂammation are relatively low.lymphocyte ratio in prediction of acute exacerbation of chronic obstructive pul-
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Figure 3 Receiver Operating Curve for neutrophil-to-lymphocyte ratio, CRP, WBC and ESR.
Table 3 Sensitivity, speciﬁcity, and cutoff point of inﬂammatory markers.
Marker Cutoﬀ AUC CI(95%) Sensitivity Speciﬁcity P
Ratio 3.12 0.878 0.899–1.003 86.7% 76.7% <0.001
CRP 3.15 0825 0.81.0–0.901 80% 87% <0.001
ESR 17.5 0.677 0.616–0.878 60% 80% 0.001
WBC 9.5 0.781 0.793–0.898 76.1% 83.3% <0.001
ESR erythrocyte sedimentation rate, CRP C-reactive protein, WCC white blood cell count.
Role of neutrophil to lymphocyte ratio in prediction of acute exacerbation of chronic obstructive pulmonary disease 5In the present study CRP showed a higher sensitivity and
speciﬁcity (80% and 86.2%) respectively than ESR. However,
it has a lower sensitivity and speciﬁcity in comparison to CRP.
Some authors reported that CRP is a good diagnostic marker
for inﬂammation [18,19]. However, others reported that it is
not a good marker because it can remain elevated for up to
three weeks after treatment, so, it can give false positive values
[17]. NLR has 86.7% sensitivity for the detection of COPD
exacerbation and 76.7% speciﬁcity. NLR appears to be the
most sensitive parameter as an indicator of exacerbated
COPD.
De Jager et al. [20] reported that both lymphocytopenia and
the NLR were better predictors of bacteremia than routine
parameters such as WBC count, CRP level, and neutrophil
count in an emergency care unit.
Our study showed that NLR increased with the severity of
airﬂow obstruction. this coincides with the study of Cockayne
et al., [16] who showed that systemic biomarkers of neutrophil
inﬂammation are associated with COPD severity as reﬂected in
the GOLD stages. This may be explained by release of oxygen
radicals and proteolytic enzymes such as neutrophil elastase
and matrix metalloproteinases, which cause tissue destruction
in the lungs.Please cite this article in press as: A.M. Yousef, W. Alkhiary, Role of neutrophil to l
monary disease, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcThere are some limitations associated with our study. First,
the population size was relatively small. Second, we did not set
a speciﬁc blood sampling time.
Conclusion: NLR can be used as a new inﬂammatory mar-
ker for assessment of inﬂammation in COPD patients. It is a
good predictor for exacerbation of COPD. It is a quick, cheap,
easily measurable with no need for a special request.
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